Mobile

Pharmacokinetics, pharmacodynamics and safety of a new Leuprolide acetate 22.5 mg depot formulation, when given as palliative treatment to prostate cancer patients

Mise à jour : Il y a 4 ans
Référence : EUCTR2006-005964-24

  • | Pays :
    • -
  • | Organes :
    • -
  • | Spécialités :
    • -

Extrait

Part A: preliminary investigation of the safety, pharmacodynamics and pharmacokinetics of a new leuprolide acetate depot 3-month formulation after i.m. or s.c. administration to patients with prostate cancer. Part B: investigation of the safety, pharmacodynamics and pharmacokinetics of a new leuprolide 3-month formulation in patients with prostate cancer after administration of a single dose of 22.5 mg leuprolide acetate by i.m. or s.c. injection (according to the results of study part A, see § 3.2).

Critère d'inclusion

  • Prostate cancer

Liens